Adherence, exposure and patients’ experiences with the use of erlotinib in non-small cell lung cancer

PURPOSE: Erlotinib is an orally administered tyrosine kinase inhibitor used for treatment of non-small cell lung cancer. Understanding actual use of medication is essential for optimizing treatment conditions. METHODS: In this multicentre prospective observational study, patients starting erlotinib...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:J Cancer Res Clin Oncol
Auteurs principaux: Timmers, Lonneke, Boons, Christel C. L. M., Moes-ten Hove, J., Smit, Egbert F., van de Ven, Peter M., Aerts, Joachim G., Swart, Eleonora L., Boven, Epie, Hugtenburg, Jacqueline G.
Format: Artigo
Langue:Inglês
Publié: Springer Berlin Heidelberg 2015
Sujets:
Original Article – Clinical Oncology
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC4469769/
https://ncbi.nlm.nih.gov/pubmed/25743274
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00432-015-1935-0
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires